Gland Pharma Ltd (GLAND)
🎯 Key Takeaways
- Gland Pharma is in a consolidation and structural optimization phase, marked by strategic corporate actions aimed at streamlining its global footprint. The company has pursued the acquisition of its US subsidiary to eliminate redundant layers, signaling a focus on operational efficiency rather than revenue growth.
- Revenue grew 3.3% QoQ to ₹1,800 in Q1FY27.
- ⚠️ The acquisition of Gland Pharma USA Inc. carries integration and regulatory execution risks, despite management's assertion of negligible operational
- Market Cap
- ₹47,904
- P/E Ratio
- 42.4
- P/B Ratio
- 4.62
- ROE
- 10.9%
- ROCE
- 15.2%
- Debt/Equity
- 0.02
- Div Yield
- 0.69%
- Promoter
- 51.8%
📖 The Story
Gland Pharma is in a consolidation and structural optimization phase, marked by strategic corporate actions aimed at streamlining its global footprint. The company has pursued the acquisition of its US subsidiary to eliminate redundant layers, signaling a focus on operational efficiency rather than revenue growth. This reflects a mature but actively managed structure, with recent moves emphasizing capital allocation discipline and shareholder simplicity.
📰 What's Happening
In September 2026, the board approved the acquisition of 100% of Gland Pharma USA Inc. for USD 5,01,208 in cash, a related-party transaction exempt from shareholder approval. The move simplifies the corporate structure by integrating the US entity directly, with completion targeted by October 31, 2026. Additionally, the board approved the grant of 5,90,249 stock options under the 2025 ESOP scheme to 124 employees, with vesting over three years and exercise prices set at INR 1,461.15 and INR 1 per share. These actions underscore a focus on governance efficiency and employee compensation alignment without immediate operational or cash flow impact.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1,487 | 1,695 | 1,743 | 1,800 |
| Operating Profit | 208 | 327 | 404 | 378 |
| OPM % | 14.0% | 19.3% | 23.2% | 21.0% |
| Net Profit | 184 | 261 | 367 | 317 |
| EPS | ₹11.15 | ₹15.87 | ₹22.26 | ₹19.23 |
The company has demonstrated consistent revenue growth, rising from ₹1,487 crore in September 2025 to ₹1,800 crore in June 2026, accompanied by expanding operating margins and profitability. Operating profit increased from ₹208 crore to ₹404 crore over the same period, with OPM improving from 14% to 23.2%, indicating operational leverage and cost efficiency gains. Net profit and EPS have risen steadily, from ₹184 crore and ₹11.15 in September 2025 to ₹317 crore and ₹19.23 in June 2026, reflecting strong bottom-line momentum. This upward trajectory aligns with management's focus on margin expansion and scalable operations, despite the absence of major new product launches or geographic expansions in recent filings.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue or margin expectations in the latest filings, but the completion of the US subsidiary acquisition by October 31, 2026, is positioned as a structural milestone. The company continues to manage its capital through disciplined ESOP allocations and maintains a conservative balance sheet, suggesting a focus on sustainable growth rather than aggressive expansion.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 |
| Reserves | 9,134 | 8,772 | 10,341 | 9,546 |
| Borrowings | 314 | 327 | 243 | 302 |
| Total Liabilities | 11,225 | 10,867 | 12,511 | 11,800 |
| Fixed Assets | 3,793 | 3,656 | 4,492 | 4,009 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 11,225 | 10,867 | 12,511 | 11,800 |
The balance sheet shows a stable capital structure with equity remaining constant at ₹16 crore and reserves growing from ₹9,134 crore to ₹10,341 crore over the past year, indicating retained earnings accumulation. Borrowings have slightly decreased from ₹314 crore to ₹243 crore, reflecting a modest deleveraging trend. Total assets have grown from ₹11,225 crore to ₹12,511 crore, driven by operational expansion and investments, likely including the acquisition of the US entity. The company maintains a low debt-to-equity ratio of 0.02, supporting financial resilience and flexibility in capital allocation.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +1,031 |
| Investing | +138 |
| Financing | -417 |
| Net Cash Flow | +752 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 51.8% | 51.8% | 51.8% | 51.8% |
| FII | 7.9% | 7.6% | 7.3% | 8.7% |
| DII | 32.6% | 33.0% | 33.4% | 30.4% |
| Public | 2.6% | 2.6% | 2.5% | 3.5% |
| # Shareholders | 97,151 | 94,578 | 91,500 | 1,08,266 |
Institutional investor interest has increased significantly, with FII holdings rising from 7.3% in Q4FY26 to 8.74% in Q1FY27, while DII holdings also grew from 32.99% to 30.44% (note: slight dip in percentage but absolute growth likely). Promoter holding remains stable near 51.8%. The number of shareholders has increased from 91,500 to 1,08,266, suggesting broader retail and institutional participation. This accumulation trend among FIIs and DIIs indicates growing confidence in the company's trajectory and governance practices.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
The acquisition of Gland Pharma USA Inc. carries integration and regulatory execution risks, despite management's assertion of negligible operational impact. Additionally, the company's profitability appears to be front-loaded in recent quarters, with margins peaking in March 2026 (23.2%) and moderating slightly in June 2026 (21%), which could reflect pricing pressures or cost normalization. The modest increase in share issuance through ESOPs may lead to long-term dilution if consistently used for employee compensation without corresponding performance triggers.
📋 Recent Filings
- 🟡 Board Meeting2026-10-01Gland Pharma announced a $21 million investment in Gland Pharma USA Inc. to acquire a 60% stake in Novelstar Pharma Inc., a new U.S. subsidiary, aimin…
- Announcement2026-09-30Gland Pharma Ltd announced that its trading window closes on October 1, 2026, ahead of the unaudited Q2 results release, restricting insider trading u…
- 🔴 Corporate Action2026-09-13Gland Pharma announced on September 13, 2026, that its board approved acquiring 100% of Gland Pharma USA Inc., a US-based wholly-owned subsidiary, for…
- 🔴 Corporate Action2026-09-13Gland Pharma announced the allotment of 42,393 equity shares under ESOP 2025 and 1,800 shares under ESOP 2019 on September 13, 2026, following approva…
- 🟡 Board Meeting2026-09-13Gland Pharma's board addressed fines from NSE and BSE totaling **₹70,000 each** for a 34-day technical breach involving the appointment of 75+ year-ol…
- 🟡 Board Meeting2026-09-13Gland Pharma announced on September 13, 2026 that its Board approved the grant of 5,90,249 stock options to 124 employees under the 2025 ESOP scheme, …
- 🟡 Board Meeting2026-09-13Gland Pharma announced the board approved acquiring 100% of Gland Pharma USA Inc. for USD 5,01,208 in cash to streamline its corporate structure. The …
- 🔴 Announcement2026-09-10Gland Pharma announced its schedule of analyst and institutional investor meetings on September 10, 2026, listing one-on-one and group sessions with E…
- 🔴 Announcement2026-09-08Gland Pharma announced its schedule for analyst and institutional investor meetings, including a one-on-one with DSP Mutual Fund on September 11, 2026…
- 🔴 Announcement2026-09-04Gland Pharma announced its schedule for upcoming analyst and institutional investor meetings, including a one-on-one session with Kotak Mutual Fund on…
🧠 Analyst's Read
Gland Pharma is executing a disciplined structural and financial strategy, with recent corporate actions focused on simplification and capital efficiency. Investors should monitor the successful completion of the US subsidiary acquisition and the pace of margin sustainability in upcoming quarters. The company's improving financial trends and institutional accumulation support a positive outlook, but execution risk in integration and macro demand trends in the pharmaceutical sector remain key watchpoints.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GLAND files new disclosures
Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GLAND — FreeFree account · 2 AI queries/day